Charles River Unveils Lentivation Platform To Expedite LVV-Based Gene Therapy Manufacturing
Portfolio Pulse from Benzinga Newsdesk
Charles River Laboratories International, Inc. (NYSE:CRL) has launched its lentiviral vector (LVV) manufacturing platform, Lentivation™, which can reduce LVV manufacturing timelines for gene and gene-modified cell therapies by up to 60 percent. This translates to fewer than seven months compared to traditional manufacturing workflows. The platform will be presented during the BioInsight's Expert Roundtable on September 27, 2023.
September 26, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Charles River Laboratories' new platform, Lentivation, could significantly expedite the manufacturing process of gene therapies, potentially giving the company a competitive edge in the market.
The launch of the Lentivation platform could significantly reduce the time it takes to manufacture gene therapies, potentially making Charles River Laboratories more competitive in the biotech industry. This could lead to increased demand for the company's services, potentially driving up its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100